MESO

Business Context and Reporting Period

Company: Mesoblast Limited (Mesoblast)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and nine months ended March 31, 2016
Business Overview: Mesoblast is a clinical-stage biotechnology company developing regenerative medicine products based on mesenchymal lineage adult stem cells (MLC). The company is dual-listed on the Australian Securities Exchange (ASX) and the NASDAQ Global Select Market. Its primary revenue sources are collaboration agreements (notably with Teva and JCR Pharmaceuticals) and milestone payments, as it has not yet generated significant revenue from direct product sales outside of Japan.

Key Financial Metrics

Note: The filing does not provide a specific "profit margin" as the company is in a loss-making development stage. Revenue is primarily derived from amortized upfront payments and milestone achievements.

Material Changes vs. Prior Period

• Revenue Composition: For the nine months ended March 31, 2016, the company recognized $3.5 million in milestone revenue from its licensee JCR Pharmaceuticals following full regulatory approval of TEMCELL® HS Inj. in Japan. This compares to $2.0 million in milestone revenue in the prior year period. Commercialization revenue increased slightly due to royalty income from TEMCELL sales launched in February 2016.
• Expense Reductions: Research and development expenses decreased by 19% ($8.6 million) for the nine-month period, driven by reduced spending on Tier 2 products and lower product support costs (salaries and share-based payments). Management and administration expenses decreased by 21% ($4.5 million) due to lower share-based payment valuations and reduced legal fees.
• Manufacturing Costs: Manufacturing commercialization expenses increased by 32% ($5.3 million) for the nine-month period. This was primarily due to a 100% increase in production runs for MSC-based clinical supply to meet demand for Tier 1 products.
• Contingent Consideration: The company recorded a $6.1 million gain from the fair value remeasurement of contingent consideration related to the Osiris acquisition for the nine months ended March 31, 2016, compared to a $7.3 million loss in the prior year period. This gain resulted from changes in valuation assumptions regarding market population and timelines.
• Foreign Exchange: The company recognized a $0.4 million foreign exchange loss for the nine months ended March 31, 2016, compared to a $10.9 million gain in the prior year. This shift occurred after the company transferred USD deposits to a USD-functional subsidiary in July 2015, reducing exposure to AUD/USD fluctuations on cash balances.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Clinical Progress: The company is actively recruiting for three Tier 1 Phase 3 trials: MPC-150-IM (chronic heart failure), MPC-06-ID (chronic low back pain), and MSC-100-IV (acute graft versus host disease in children). The Phase 3 trial for chronic heart failure was optimized to reduce patient numbers from 1,165 to approximately 600 following FDA agreement on a new primary endpoint.
• Commercialization: TEMCELL® HS Inj. was launched in Japan in February 2016. The company expects to continue incurring significant losses as it advances clinical programs and prepares for potential commercialization.
• Liquidity: Management stated that cash and cash equivalents of approximately $100 million as of March 31, 2016, are sufficient to fund operations for at least the next 12 months. The company anticipates needing additional capital in the future, potentially through equity offerings, debt, or collaborations.

Risks and Contingencies

• Profitability: The company has incurred losses since inception and does not expect to achieve profitability in the foreseeable future. Future profitability depends on successful regulatory approvals and commercialization.
• Capital Requirements: Failure to raise additional capital could force the company to delay, scale back, or terminate product development programs.
• Regulatory and Clinical Risks: There is no assurance that product candidates will receive regulatory approval. Clinical trials may fail to demonstrate safety or efficacy, or patient enrollment may be delayed.
• Manufacturing Dependence: The company relies on third-party manufacturers (specifically Lonza) for clinical and commercial supply. Disruptions in these relationships or manufacturing processes could harm operations.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting due to limited accounting personnel and a lack of segregation of duties. Management is implementing remediation plans.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $99.9 million cash balance to fund operations through the next 12 months, considering the high burn rate of clinical trials.
• Revenue Recognition: Confirm the sustainability of revenue streams, which are heavily reliant on amortized upfront payments from the Teva agreement and milestone payments from JCR, rather than recurring product sales.
• Contingent Consideration Volatility: Monitor the fair value of the $92.7 million contingent consideration liability, as changes in assumptions (market size, pricing, timelines) can cause significant non-cash gains or losses that distort operating results.
• Internal Control Remediation: Track the progress of remediation efforts regarding the material weakness in internal controls over financial reporting to ensure future financial statement reliability.
• Clinical Trial Milestones: Monitor enrollment and data readouts for the three active Phase 3 trials (CHF, CLBP, aGVHD), as these are critical catalysts for future valuation and potential revenue.